Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of MARINOMED BIOTECH AG
No Price
Closing Price XWBO 31.07.2026:
5,40 EUR
31.07.2026 11:35
Current Prices from MARINOMED BIOTECH AG
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
WIENER BOERSE AG
MARI.VI
EUR
31.07.2026 11:35
5,40 EUR
-
Quotrix
MBAGIAD6.DUSD
EUR
30.07.2026 09:36
5,25 EUR
-
Düsseldorf
MBAGIAD6.DUSB
EUR
23.07.2026 17:30
5,45 EUR
-
Share Float & Liquidity
Free Float68,60 %
Shares Float1,37 M
Shares Outstanding2 M
Company Profile for MARINOMED BIOTECH AG Share
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
